In this series, DDW speaks to women in leading positions across biopharma about the work they’re doing and their experiences within the industry. Here, we speak to Charlotte Edenius, Gesynta, co-founder and VP of R&D Strategy of Gesynta Pharma about the company’s approach to treating pain and inflammation and… Read More
DDW Editor Reece Armstrong speaks to David Crean, Chief Business Officer of biopharmaceutical company MediciNova, about recent turmoil within the FDA and what the pharma sector should expect from the agency going forward. It’s been a volatile couple of years for the United States. President Trump’s second term… Read More
GSK has reached an agreement to acquire biopharmaceutical company Nuvalent for $10.6 billion. The agreement includes GSK’s purchase of three therapies for lung cancer, including Zidesamtinib (NVL-250) and neladalkib (NVL-655). The candidates are late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of non-small cell… Read More
Brain health company Angelini Pharma has acquired biopharmaceutical company Catalyst Pharmaceuticals in a deal worth $4.1 billion. Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, worth an overall $4.1 billion, in a move that allows the company to enter the US market… Read More
City St George’s is partnering with drug development company Paradigm Biopharmaceuticals to test a drug that could become a new treatment option for osteoarthritis. The UK-Australian partnership will investigate the effect of injectable pentosan polysulfate sodium (iPPS) – a drug currently being trialled for knee osteoarthritis by Paradigm Biopharmaceuticals… Read More
James L Sherley, MD, PhD, explores how a new method for quantifying stem cells in mesenchymal tissue samples can lead to better drug development for stem cell therapies. Mesenchymal tissue cell samples are considered incredibly promising for the development of new stem cell therapies. These samples can be based on bone… Read More
The first patient has been dosed in a trial for an investigational Tourette syndrome therapy. Biopharmaceutical company Emalex Biosciences announced that the first patient was dosed in its expanded access programme for ecopipam, an investigational first-in-class D1 receptor antagonist in development for the treatment of Tourette syndrome. … Read More
An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows. Valiltramiprosate, which received Fast Track designation from the US Food and Drug Administration (FDA) in 2017, is an investigational oral agent being evaluated as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease… Read More
A surge in mergers and acquisitions (M&A) boosted the biopharma market by $36 billion at the end of 2025, a new report finds. Evaluate’s 2026 Preview Report shows $36 billion was generated through M&A last October and November, largely through biotech buyout. The report predicts M&A will continue to play an… Read More
Biotechnology company Relief Therapeutics has announced a business combination with commercial-stage company NeuroX to create a new digital neurotherapeutics company. The business combination follows approval from Relief’s shareholders, who have also approved a capital increase through the issuance of 140 million new ordinary shares. The business combination is… Read More
Nearly three out of five biopharma professionals (58%) believe their company’s potential is restricted by rigidity in daily strategic decision-making. Research commissioned by Nmblr revealed that strategic misalignment is endemic across the industry, threatening both speed to market and the ability to adapt in real-time. … Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s leading story came from a positive development in biopharma, with top companies… Read More
News round-up for 3 – 7 November by Bruno Quinney, Content Team at DDW. This week’s leading story is a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a… Read More
Specialty pharmaceuticals company Cumberland Pharmaceuticals has invested $4 million in Talicia, the global product developed by biopharmaceutical company RedHill Biopharma. Talicia is the number one branded US gastroenterologist-prescribed H. pylori therapy, listed as a first-line H. pylori therapy in American College of Gastroenterology Clinical Guidelines. It remains the only FDA-approved all-in-one,… Read More
AstraZeneca has become the latest company to lower the cost of medicines for American patients. The company recently announced an agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients “while preserving America’s cutting-edge biopharmaceutical innovation”. In July, US President Donald… Read More
The ATR inhibitor alnodesertib has been granted fast track designation by the US Food and Drug Administration (FDA), biopharmaceutical company Artios Pharma Limited has announced. Alnodesertib is a treatment for adult patients with ATM negative metastatic colorectal cancer (mCRC) in the third-line setting, in combination with a… Read More
